Our technology offers an entry into linear and cyclic peptide drugs, small proteins, (bio)conjugates, Antibody Drug Conjugates, PROTACs and LYTACs.
Read our latest news and stay updated
EnzyTag to present at the virtual Biologics Series in the Peptides and Oligonucleotides program on August 27 –
Please feel free to contact us
EnzyTag is open to further discussions on technology licensing for commercial purposes.